Participants with non-alcoholic fatty liver disease ( defined as ( 1 ) H magnetic resonance spectroscopy liver-fat content > 556 % ) , insulin resistance ( homoeostatic model assessment of insulin resistance [ HOMA-IR ] of at least 20 mmol/LmU/L ) , BMI greater than 27 kg/m ( 2 ) , and aged 35-65 years were randomly assigned by interactive voice response system in a 1:1 ratio , stratified for triglyceride concentration ( < 17 mmol/L or 17 mmol/L ) , to oral RO5093151 ( 200 mg twice daily ) or matching placebo for 12 weeks .